Table 1 Antimicrobial activities of ZnO2 NPs and doped ZnO2 NPs (with and without ligand capping) against MRSA (a) and BC (b). All experiments were performed in triplicates (N = 3), while the concentrations were presented as (μg/ml)
Compounds | Zone of inhibition (mm) for Methicillin-resistant Staphylococcus aureus, concentration = µg/ml, N = 3 (triplicates) | |||
|---|---|---|---|---|
250 µg/ml | 500 µg/ml | 750 µg/ml | 1000 µg/ml | |
(a) | ||||
ZnO2-NPs | 6.1 ± 1.5 | 6.2 ± 1.7 | 7.2 ± 1.6 | 7.7 ± 0.9 (MIC) |
3% Mn-doped ZnO2 | 6.2 ± 2.4 (MIC) | 6.3 ± 2.1 (MBC) | 7.6 ± 2.1 | 8.9 ± 1.7 |
5% Co-doped ZnO2 cit | 9.2 ± 1.7 | 9.5 ± 1.5 (MIC/MBC) | 12.2 ± 2.7 | 12.5 ± 2.0 |
3% Mn-doped ZnO2 dmlt | 6.2 ± 2.6 (MIC/MBC) | 6.5 ± 2.0 | 8.3 ± 2.6 | 10.3 ± 1.7 |
Negative control | 0.0 ± 0 | 0.0 ± 0 | 0.0 ± 0 | 0.0 ± 0 |
Ciprofloxacin | 13.3 ± 2.0 | 13.3 ± 2.6 | 15.4 ± 2.4 | 14.2 ± 3.0 |
Compounds | Zone of inhibition (mm) for Bacillus cereus (BC), concentration = µg/ml, N = 3 (triplicates) | |||
|---|---|---|---|---|
250 µg/ml | 500 µg/ml | 750 µg/ml | 1000 µg/ml | |
(b) | ||||
ZnO2-NPs | 7.5 ± 2.0 | 7.9 ± 1.7 | 8.0 ± 2.1 | 8.6 ± 0.9 (MIC) |
3% Mn-doped ZnO2 | 9.0 ± 1.6 | 10 ± 2.1 (MIC) | 10 ± 2.6 | 11 ± 1.9 |
5% Co-doped ZnO2 cit | 6.2 ± 1.7 | 6.3 ± 2.1 (MIC/MBC) | 6.3 ± 1.5 | 6.4 ± 1.5 |
3% Mn-doped ZnO2 dmlt | 6.2 ± 2.4 (MIC) | 6.3 ± 2.2 (MBC) | 11.4 ± 2.3 | 12.3 ± 1.9 |
Negative control | 0.0 ± 0 | 0.0 ± 0 | 0.0 ± 0 | 0.0 ± 0 |
Ciprofloxacin | 14.1 ± 2.5 | 15.5 ± 2.6 | 15.6 ± 2.6 | 17.5 ± 1.9 |
